REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 ...

Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said: Using our integrated 'right targets, right vectors, right patients, right time' approach, we aim to address the unmet clinical ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...

Title: Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic ...